Contact Us
Click "Review Abstract" Links Below to Review Journal Articles

References:
  1. Bang H et al. Arthritis Rheum
    2007; 56(8):2503-2511. (review abstract)
  2. Mathsson L et al. Arthritis Rheum.
    2008; 58(1):36-45. (review abstract)
  3. Innala L et al. J Rheumatol.
    2008; 35(6):1002-1008. (review abstract)
  4. Ursum J et al. Arthritis Res Ther.
    2008; 10(1):R12. (review abstract)
  5. Dejaco C et al. Arthritis Res Ther.
    2006; 8(4):R119. (review abstract)
  6. Bizzaro N et al. Clin Chem
    2007; 53(8):1527-1533. (review abstract)
  7. Coenen D et al. Clin Chem
    2007; 53(3):498-504. (review abstract)
  8. Soos L et al. J Rheumatol
    2007; 34(8):1658-1663. (review abstract)
  9. Exagen Diagnostics, Inc. Data on file.

Healthcare Professionals

Avise MCV

A sensitive and specific test that improves upon traditional means of diagnosing rheumatoid arthritis (RA) [1].

AVISE MCV detects autoantibodies to mutated citrullinated vimentin (MCV). MCV is a naturally occurring protein isoform that is found within the inflamed synovium of patients with RA, whereas other citrullinated peptide markers use a synthetic antigen composition.

Avise MCV is a useful adjunct to traditional clinical and laboratory methods for diagnosing RA. Several studies have established the clinical performance of anti-MCV in diagnosing RA. The clinical performance of anti-MCV versus anti-CCP across eight peer reviewed studies can be summarized as follows:

8 studies; total number of patients: N=3524;

Patients with rheumatoid arthritis: N=2232; controls: N=1292

* Anti-CCP studies include tests from multiple manufacturers

and generations:anti-CCP2, anti-CCP3, anti-CCP 3.1

* Studies included anti-CCP tests from multiple manufacturers and generations: anti-CCP2 and anti-CCP3.1.

Avise MCV offers a high level of diagnostic accuracy as well as helps to identify patients who are likely to have more severe disease progression [2]. Graphs below illustrate the difference over a five year period in two common clinical parameters of RA patients who are positive versus negative at baseline.

Avise MCV has a unique diagnostic spectrum, meaning that it will be positive even in a certain percentage of patients who are negative for both anti-CCP and RF. The diagram below illustrates the findings from one study where 10% of early RA patients were positive for Avise MCV, but negative for RF and anti-CCP. [9]

 

Diagram of Lab Marker Sensitivity

(n=470; Sensitivity in patients who developed RA within an inception cohort of undifferentiated arthritis patients) [9]. The sensitivity for Anti-MCV, Anti-CCP2, and RF in this study was 63%, 53% and 48% respectively.

Early diagnosis and appropriate treatment of rheumatoid arthritis are critically important to prevent erosive joint destruction and disability. Anti-MCV testing provides the potential to better detect patients who have RA and identify those likely to experience more severe disease progression.

Avise MCV results are provided on a color graph to facilitate easy interpretation and dialogue with patients. Below is an example of the result report.